Document Detail


Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
MedLine Citation:
PMID:  14752797     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Although age <1 year at diagnosis has been associated with a worse prognosis in rhabdomyosarcoma (RMS), the relationship of age at diagnosis to clinical presentation and outcome has not been evaluated carefully. We reviewed data from recent Intergroup Rhabdomyosarcoma Study Committee (later called Group, IRSG) trials to examine this relationship in order to estimate prognosis more accurately and further refine treatment. PROCEDURE: We used data from IRS-III, -IV Pilot, and -IV (1983-97, N=2,343) to study the relationship of patient age with clinical features and prognosis in a large cohort of patients treated with contemporary therapy. RESULTS: We showed that, after adjusting for important prognostic factors, age was an independent risk factor for treatment failure and patients could be classified into three failure-risk categories based on age (i.e., <1 year; 1-9 years; >10 years). Infants and adolescents were more likely to have unfavorable features, including alveolar or undifferentiated tumors and advanced Group and Stage, and also had significantly poorer failure-free survival (FFS) than did children aged 1-9 (53 and 51% vs. 72%, P<0.001). Although there was a difference in FFS among age categories, there was no evidence that age influences outcome within the three categories. CONCLUSIONS: Since age relates independently to outcome after adjustment for known risk factors, it is likely that other factors, including perhaps patients' tolerance of protocol-specified therapy, explain this relationship.
Authors:
D Joshi; James R Anderson; C Paidas; J Breneman; D M Parham; W Crist;
Related Documents :
22564907 - Gender difference in age at onset of schizophrenia: a meta-analysis.
24863217 - Biofabrication of ag nanoparticles using sterculia foetida l. seed extract and their to...
22524297 - "positive biology": the centenarian lesson.
24784027 - Micrornas in human skin ageing.
12439867 - Protective effect of arabic gum against cardiotoxicity induced by doxorubicin in mice: ...
15642857 - Blood pressure levels before dementia.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Pediatric blood & cancer     Volume:  42     ISSN:  1545-5009     ISO Abbreviation:  Pediatr Blood Cancer     Publication Date:  2004 Jan 
Date Detail:
Created Date:  2004-01-30     Completed Date:  2004-02-17     Revised Date:  2009-01-12    
Medline Journal Info:
Nlm Unique ID:  101186624     Medline TA:  Pediatr Blood Cancer     Country:  Unknown    
Other Details:
Languages:  eng     Pagination:  64-73     Citation Subset:  IM    
Copyright Information:
Copyright 2003 Wiley-Liss, Inc.
Affiliation:
Department of Hematology/Oncology, Nemours Children's Clinic, Orlando, Florida, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Age Factors
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Child
Child, Preschool
Clinical Trials as Topic
Combined Modality Therapy
Disease-Free Survival
Female
Humans
Infant
Male
Prognosis
Radiotherapy
Rhabdomyosarcoma / diagnosis*,  therapy
Risk Factors
Soft Tissue Neoplasms / diagnosis*,  therapy
Survival Rate
Treatment Outcome
United States / epidemiology
Grant Support
ID/Acronym/Agency:
CA24507/CA/NCI NIH HHS; CA72989/CA/NCI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stature of young people with malignant bone tumors.
Next Document:  Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncolo...